HMG-CoA reductase inhibitors (statins) have led to remarkable protection from cardiovascular (CV) morbidity and mortality in patients with CV disease or CV risk factors. However, despite the high burden of CV disease in patients with ESRD, studies have not demonstrated the same benefit in this patient population.